Zacks Investment Research on MSN
CPRX's Agamree shows potential beyond DMD after positive phase I data
Catalyst Pharmaceuticals CPRX has reported positive top-line results from an early-stage study evaluating Agamree (vamorolone ...
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...
Catalyst Pharmaceuticals is fairly valued, with growth reliant on acquired assets Firdapse, Agamree, and Fycompa, but lacks an internal pipeline. CPRX's revenue growth faces headwinds: Firdapse's ...
Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.
Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of ...
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
Hosted on MSN
Does Catalyst (CPRX) Have the Potential to Rally 36.22% as Wall Street Analysts Expect?
Catalyst Pharmaceutical (CPRX) closed the last trading session at $24.96, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set ...
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results